BIOCON IN PACT WITH US FIRM FOR DIABETES DRUG DEVELOPMENT

BIOCON has invigorated its diabetics drug development drive by teaming up with US based biopharma player Amylin Pharmaceuticals. The companies have entered into an exclusive co-development and marketing partnership for a peptide hybrid or phybrid. This phybrid will combine properties of two peptides - essentially small proteins - into one molecule to treat diabetes. ?For instance, this bifunctionality could lower glucose levels as well as induce weight loss.
"Against using single properties on their own, this technology is likely to give a differentiated clinical outcome by enabling the interplay of two peptides with dual benefits (like lower sugar level and weight loss)," COO of Biocon Arun Chandavarkar, told Economic Times.